OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review

Movement Disorders Clinical Practice

Volumn 3, Issue 2, 2016, Pages 109-115

  Dashtipour, Khashayar ^a   Chen, Jack J ^a,b   Espay, Alberto J ^c   Mari, Zoltan ^d   Ondo, William ^e  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MARSHALL B KETCHUM UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

AbobotulinumtoxinA; Blepharospasm; Botulinum toxin; Cervical dystonia; Dose conversion ratio; OnabotulinumtoxinA

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; BLEPHAROSPASM; CERVICAL DYSTONIA; DATA EXTRACTION; DOSIMETRY; DRUG EFFICACY; DYSPHAGIA; HUMAN; MUSCLE WEAKNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT ASSESSMENT;

EID: 85031722824     PISSN: None     EISSN: 23301619     Source Type: Journal    
DOI: 10.1002/mdc3.12235     Document Type: Article

References (24)

1. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002;18(6 Suppl):S119-S124.
2. Allergen. Botox (onabotulinumtoxinA) [Prescribing Information]. Irvine, CA: Allergan, Inc.; 2014.
3. Ipsen Biopharmaceuticals. Dysport® for Injection (abobotulinumtoxinA) [Prescribing Information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; 2013.
4. Solstice Neurosciences. Myobloc (rimabotulinumtoxinB) Injection [Prescribing Information]. South San Francisco, CA: Solstice Neurosciences, Inc.; 2010.
5. Merz Pharmaceuticals. Xeomin (incobotulinumtoxinA) [Prescribing Information]. Greensboro, NC: Merz Pharmaceuticals, LLC; 2014.
6. Chen JJ, Dashtipour K. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. Pharmacotherapy 2013;33:304-318.
7. Allergan Pharmaceuticals. BOTOX COSMETIC (onabotulinumtoxinA) for Injection, for Intramuscular Use [Prescribing Information]. Irvine, CA: Allergan, Inc.; 2013.
8. ®) in an LD50 assay. J Neural Transm 2012;119:13-15.
9. Mclellan K, Das RE, Ekong TA, Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996;34:975-985.
10. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994;87:719.
11. Pickett A, O'Keeffe R, Panjwani N. The protein load of therapeutic botulinum toxins. Eur J Neurol 2007;14:e11.
12. ®. Drugs R D 2010;10:67-73.
13. Pickett A. Consistent biochemical data are essential for comparability of botulinum toxin type A products. Drugs R D 2011;11:97-98.
14. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther 2007;32:387-402.
15. Rystedt A, Nyholm D, Naver H. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia. Clin Neuropharmacol 2012;35:278-282.
16. Bentivoglio AR, Ialongo T, Bove F, De Nigris F, Fasano A. Retrospective evaluation of the dose equivalence of Botox((R)) and Dysport ((R)) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci 2012;33:261-267.
17. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord 2013;28:1775-1783.
18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
19. Nestor MS, Ablon GR. Duration of action of abobotulinumtoxina and onabotulinumtoxina: a randomized, double-blind study using a contralateral frontalis model. J Clin Aesthet Dermatol 2011;4:43-49.
20. Nestor MS, Ablon GR. Comparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral Frontalis model and the Frontalis Activity Measurement Standard. J Drugs Dermatol 2011;10:1148-1157.
21. ® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
22. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-462.
23. Yun JY, Kim JW, Kim HT, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord 2015;30:206-213.
24. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997;235:197-199.